<DOC>
	<DOCNO>NCT02626234</DOCNO>
	<brief_summary>study aim assess effect INC280 pharmacokinetics digoxin rosuvastatin patient cMET-dysregulated advanced solid tumor</brief_summary>
	<brief_title>A Drug-drug Interaction ( DDI ) Study Assess Effect INC280 Pharmacokinetics Digoxin Rosuvastatin Patients With cMET-dysregulated Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients must : advanced solid tumor confirm cMET dysregulation least one measurable lesion define RECIST 1.1. recover toxicity relate prior anticancer therapy adequate organ function ECOG performance status ( PS ) 0 1 Patients must : know hypersensitivity excipients INC280 prior treatment cMET HGFtargeting inhibitor know hypersensitivity digoxin rosuvastatin excipients symptomatic central nervous system ( CNS ) metastases neurologically unstable presence history carcinomatous meningitis history another primary malignancy currently clinically significant currently require active intervention Clinically significant , uncontrolled heart disease , include QTcF ≥ 450 msec ( male patient ) , ≥ 460 msec ( female patient ) screen ECG Thoracic radiotherapy lung field ≤ 4 week prior start INC280 Major surgery within 4 week prior start INC280 Patients receive unstable increase dos corticosteroid . Impairment GI function GI disease may significantly alter absorption INC280 Patients receive , expect receive digoxin rosuvastatin within 21 day prior begin DDI phase ( Day 1 ) duration DDI phase . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cMET , INC280 , rosuvastatin , digoxin</keyword>
</DOC>